**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

---

1. Name and Address of Reporting Person
   - Akinsanya Karen
     - (Last) C/O SCHRODINGER, INC.,
     - (First) 1540 BROADWAY, 24TH FLOOR
     - (Middle) NEW YORK
     - (City) NY
     - (State) 10036
     - (Zip) 10160

2. Issuer Name and Ticker or Trading Symbol
   - Schrodinger, Inc. [SDGR]

3. Date of Earliest Transaction (Month/Day/Year)
   - 10/15/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)
   - X

5. Relationship of Reporting Person(s) to Issuer
   - (Check all applicable)
     - 10% Owner
     - Director
     - Officer (give title below)
     - See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)
   - X Form filed by One Reporting Person
     - Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Security</th>
<th>Date</th>
<th>Transact.</th>
<th>Qty</th>
<th>Price</th>
<th>Owned Following</th>
<th>Form Filed By</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>10/15/2021</td>
<td>A</td>
<td>1,393</td>
<td>$4.34</td>
<td>1,393</td>
<td>X</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/15/2021</td>
<td>D</td>
<td>1,393</td>
<td>$55.75</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Security</th>
<th>Date</th>
<th>Transaction</th>
<th>Qty</th>
<th>Price</th>
<th>Owned Following</th>
<th>Form Filed By</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (right to buy)</td>
<td>10/15/2021</td>
<td>A</td>
<td>1,393</td>
<td>$4.34</td>
<td>1,393</td>
<td>X</td>
</tr>
</tbody>
</table>

---

**Explanation of Responses:**

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.
2. This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.

**Remarks:**

EVP, Chief Biomedical Scientist, Head of Discovery R&D

/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya

10/19/2021

**Signature of Reporting Person**

Date

---

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

---

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.